Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenuePayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Coya Therapeutics (COYA) over the last 4 years, with Q3 2025 value amounting to $28.1 million.

  • Coya Therapeutics' Cash & Equivalents fell 955.03% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year decrease of 955.03%. This contributed to the annual value of $38.3 million for FY2024, which is 1751.01% up from last year.
  • Coya Therapeutics' Cash & Equivalents amounted to $28.1 million in Q3 2025, which was down 955.03% from $29.8 million recorded in Q2 2025.
  • Over the past 5 years, Coya Therapeutics' Cash & Equivalents peaked at $38.3 million during Q4 2024, and registered a low of $5.9 million during Q4 2022.
  • For the 4-year period, Coya Therapeutics' Cash & Equivalents averaged around $26.2 million, with its median value being $30.4 million (2024).
  • Per our database at Business Quant, Coya Therapeutics' Cash & Equivalents soared by 44985.52% in 2023 and then crashed by 1857.92% in 2025.
  • Quarter analysis of 4 years shows Coya Therapeutics' Cash & Equivalents stood at $5.9 million in 2022, then surged by 449.86% to $32.6 million in 2023, then increased by 17.51% to $38.3 million in 2024, then decreased by 26.63% to $28.1 million in 2025.
  • Its Cash & Equivalents was $28.1 million in Q3 2025, compared to $29.8 million in Q2 2025 and $35.5 million in Q1 2025.